Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Riwayat: Educational Journal of History and Humanities Media Penelitian dan Pengembangan Kesehatan
Berliana, Dini
Unknown Affiliation
Humanities Biochemistry, Genetics & Molecular Biology Decision Sciences, Operations Research & Management Dentistry Education Environmental Science Medicine & Pharmacology Social Sciences

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
An Updated Review of Goserelin as Ovarian Protection in Premenopausal Breast Cancer Berliana, Dini; Yulistiani, Yulistiani
Riwayat: Educational Journal of History and Humanities Vol 6, No 4 (2023): Educational, Historical Studies and Humanities
Publisher : Universitas Syiah Kuala

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24815/jr.v6i4.36208

Abstract

Premenopausal breast cancer is a serious medical challenge, with treatment focusing on inhibiting estrogen production to stop the growth of cancer cells. Goserelin, a gonadotropin hormone (GnRH) agonist, has been used to protect the ovaries and reduce estrogen levels in premenopausal women undergoing breast cancer therapy. Previous studies have provided evidence of Goserelin's efficacy and safety, but understanding continues to evolve. Therefore, we conducted this study to provide a recent update on the role of Goserelin in ovarian protection in premenopausal breast cancer. This study is an updated review that summarizes the relevant scientific literature on the use of Goserelin in ovarian protection in premenopausal breast cancer. We examined clinical research, randomized trials, and observational studies published in several leading academic databases. The results of these studies were analyzed and organized in the context of ovarian protection and therapeutic effects on patients. A review of the literature indicates that Goserelin remains an effective option in reducing estrogen levels in premenopausal women with breast cancer. Recent studies show continuity in Goserelin's role in reducing the risk of ovarian failure and side effects associated with estrogen inhibition, such as premature menopause. Apart from that, giving Goserelin in the form of monthly and 3-monthly implants is equally effective in controlling estrogen levels.
Association of medication adherence with clinical outcomes and quality of life in type 2 diabetes mellitus patients: a cross-sectional study Fandinata, Selly Septi; Putra, Deddy Aryanda; Lubada, Eziah Ika; Sari, Silfiana Nisa Permata; Devientasari, Chinthia; Ernawati, Iin; Suryandari, Mercyska; Berliana, Dini
Media Penelitian dan Pengembangan Kesehatan Vol. 36 No. 1 (2026): MEDIA PENELITIAN DAN PENGEMBANGAN KESEHATAN
Publisher : Poltekkes Kemenkes Bandung

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.34011/jmp2k.v36i1.2218

Abstract

Background: Type 2 diabetes mellitus is a chronic metabolic disorder characterized by elevated blood glucose levels. Patient adherence to medication is a critical factor in effective management, as it can reduce morbidity and mortality while improving health-related quality of life (HRQoL). Digital interventions, such as smartphone-based medication reminder applications, represent a promising strategy to enhance adherence. Objective: This study aimed to examine the relationship between medication adherence and clinical outcomes, specifically fasting blood glucose levels and HRQoL, among patients with type 2 diabetes in primary health care settings. Methods: A cross-sectional pre–post test design was employed involving 96 respondents, divided equally into control and intervention groups, selected through convenience sampling. Primary data were collected using the MARS-10 adherence questionnaire and the DQOL Brief Clinical Inventory, while secondary data were obtained from pre– and post–fasting blood glucose measurements. Results: Results showed no significant relationship between medication adherence and fasting blood glucose levels (p > 0.05), nor between adherence and HRQoL (p > 0.05), even with the implementation of the Drug Reminder App intervention. Conclusion: These findings highlight the need for additional interventions or further innovations in digital adherence support to improve clinical and quality-of-life outcomes in type 2 diabetes management.
Co-Authors Devientasari, Chinthia Ernawati, Iin Eziah Ika Lubada Mercyska Suryandari Putra, Deddy Aryanda Sari, Silfiana Nisa Permata Septi Fandinata, Selly Yulistiani Yulistiani, Yulistiani